Objective: The aim of this study was to determine whether or not the titre of thyroid-stimulating hormone receptor antibody with stimulating (TRAb-S) activity changes in patients with Graves' disease (GD) or toxic multinodular goitres (TMNG) 3 months after treatment with sodium iodide ( 131 I). Subjects and Methods: Serum specimens were obtained from 21 hyperthyroid patients (15 with GD and 6 with TMNG) at a median 0.5 months before and 3 months after 131 I treatment using a standard ablative dose of 555 MBq. TRAb-S activity was measured in a sensitive and specific luminescent bioassay employing the lulu cell line and expressed as a stimulation index (SI; normal ^1.5). Results: The mean TRAb-S in the GD patients was 2.72 SI (95% CI: 1.51-4.03) 0.5 months before administration of 131 I and 3.98 SI (95% CI: 1.20-6.76) 3 months after administration of 131 I. The difference was not statistically significant at p ! 0.8. It was not elevated in the TMNG patients before (0.57 SI; 95% CI: 0.41-0.73) and after (1.00 SI; 95% CI: 0.74-1.26) treatment either. Conclusions: Radioiodine therapy for GD or TMNG did not induce a significant change in TRAb-S activity at 3 months after treatment with 131 I, probably due to effective antithyroid therapy or the timing of samples.
Introduction
Sodium iodide-131 ( 131 I) is increasingly advocated as the definitive treatment of choice in patients with hyperthyroidism [1] . Changes that occur in thyroid autoimmunity after treatment of Graves' disease (GD) with 131 I include a rise in thyroid-stimulating hormone receptor antibody with stimulating (TRAb-S) activity [2, 3] . Longterm changes in the titre of TRAb-S that may influence thyroid function have been noted years after 131 I treatment [4] . Chiovato et al [5] observed a significant increase in TRAb-S 6 months after 131 I treatment in patients who later developed hypothyroidism, and they postulated that the release of thyroid-stimulating hormone receptor (TSH-R) molecules from follicular cells as a consequence of radioiodine-induced thyroid cell damage may boost the immune response and result in the increased TRAb-S activity. Thus the TRAb-S status following 131 The aim of this study was to determine whether or not the autoimmune changes in TRAb-S activity in serum of hyperthyroid patients treated with an ablative dose of 131 I appear earlier than previously reported by using a highly sensitive and specific human TSH-R bioassay.
Subjects and Methods
Twenty-one hyperthyroid subjects, 15 with GD and 6 with toxic multinodular goitres (TMNG), were included in the study. GD was diagnosed on clinical features plus the presence of elevated serum thyrotropin-binding-inhibiting immunoglobulin (TBII) titres (1 15% inhibition), and TMNG was also diagnosed on clinical features plus undetectable TBII titres. A 131 I thyroid scan performed on the day of ablative treatment was used as additional evidence for diagnosis and to confirm a 4-hour uptake 1 4% as indicative of satisfactory iodide trapping. Carbimazole was used as the antithyroid therapy of choice to render patients euthyroid, maintained up to 5 days prior to 131 I therapy, resumed 72 h after treatment and finally discontinued 6 weeks later. Each patient was given a standard ablative dose of 555 MBq (15 mCi). Paired serum samples were obtained at a median 0.5 months before and 3.0 months after 131 I treatment, and TRAb-S activity was measured in a luminescent bioassay using the lulu cell line (Chinese hamster ovary cells stably transfected with human TSH receptor and a cyclic-adenosine-monophosphate-dependent luciferase-responsive reporter) [6] . Lulu cells were seeded in 96-well plates, and serum was added at 10%. Luciferase expression was quantified as emission of light in the presence of luciferin. Results were expressed as a stimulation index (SI) of light output from a subject's serum to light output from control serum. The 97.5 percentile of euthyroid serum (1.5 SI) was used as the cut-off. The Mann-Whitney U test was used to assess statistical significance.
Results
The mean TRAb-S activity in the patients with GD was 2.72 (1.51-4.03) and 3.98 (1.20-6.76) at 0.5 months before and 3 months after 131 I therapy, respectively. The corresponding SI values for patients with TMNG were 0.57 (0.41-0.73) and 1.00 (0.74-1.26; fig. 1 ). The difference in titre before and after treatment was not statistically significantly different (p ! 0.8). In the GD group, 8 of the 15 subjects had elevated TRAb-S activity before radioiodine treatment. Seven continued to have a raised activity at 3 months whilst 1 returned to normal. Two subjects with normal pretreatment TRAb-S developed increased activity after treatment. None of the 6 patients with TMNG had elevated TRAb-S activity either before or after treatment. Fig. 1 . Mean TRAb-S activity 0.5 months before and 3 months after ablative radioiodine therapy in hyperthyroid subjects with GD and TMNG. TRAb-S activity is expressed as an SI (normal ^1.5). Error bars represent 95% confidence intervals.
Discussion
Three months after a standard ablative dose of 131 I had been administered to patients with GD pretreated with carbimazole, TRAb-S activity as measured in a sensitive and specific human TSH-R bioassay showed no significant change probably due to effective antithyroid drug therapy and/or earlier sampling of serum than previously reported [5] . It seems that changes in the titre of TRAb-S do not occur 3 months after ablative treatment with 131 I; however, further studies will be required to confirm this observation.
An increase in TRAb-S titres has been reported following 131 I treatment in some patients with TMNG and variously interpreted as the induction of autoimmunity by 131 I-induced thyroid cell damage, the unmasking of preexisting GD or a temporary side-effect without further clinical relevance [7, 8] . In this study, we did not observe a similar effect on TMNG patients as the serum sampling was done earlier than 6 months. It should also be noted that the sample size of this study was small.
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Conclusion
In this study on 21 hyperthyroid patients, a significant change in TRAb-S activity was not noticed 3 months after treatment with 131 I, probably due to effective antithyroid therapy or the timing of samples.
